These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 10848699)

  • 41. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(2):601-6. PubMed ID: 25684494
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The significance of early detection for prostate cancer in mass screening].
    Kato M; Tammbo M; Yoshimatsu T; Ohta M; Kinjyo M; Noda H; Watanabe K; Miyata A; Murata A; Miura I; Yoneda T; Yoshii M; Okegawa T; Kojima M; Sayama T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):23-9. PubMed ID: 11235139
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
    Stenman UH; Hakama M; Knekt P; Aromaa A; Teppo L; Leinonen J
    Lancet; 1994 Dec; 344(8937):1594-8. PubMed ID: 7527116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
    de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
    Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
    Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
    Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
    Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.
    Larsen SB; Brasso K; Iversen P; Christensen J; Christiansen M; Carlsson S; Lilja H; Friis S; Tjønneland A; Dalton SO
    Eur J Cancer; 2013 Sep; 49(14):3041-8. PubMed ID: 23684783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations.
    Ito K; Kubota Y; Suzuki K; Shimizu N; Fukabori Y; Kurokawa K; Imai K; Yamanaka H
    Urology; 2000 May; 55(5):705-9. PubMed ID: 10792085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
    Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of serum free prostate specific antigen in the screening of prostate cancer.
    Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
    J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
    Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
    Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
    Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.